The Biostatistics and Computational Biology Core of the Cancer Center was established in 1994 with the goal of assuring appropriate biostatistical support to cancer-related research at UCSF. In 2011, at the suggestion of an external advisory board, the Core was split into two separate cores: 1) Biostatistics Core and 2) Computational Biology Core. This division was undertaken as a reflection of the distinct needs of projects focusing on clinical and laboratory studies involving standard statistical approaches and those involving genomics and requiring high performance computing services. Because some projects may require both types of support, the Cores are closely coordinated. There is no overlap of services provided by each core, and funding is not duplicated for the same services in two cores. The major functions of the Biostatistics Core include: (1) Consultation services for experimental design and data analysis for clinical, epidemiological and laboratory studies conducted through the Cancer Center;(2) grant development services, including experimental design, sample size planning, preliminary data analyses and writing;(3) support for protocol review and data safety monitoring for proposed and ongoing studies through PRMS and DSMC;and (4) education, in both formal and informal settings. The Core provides partial support to nine statisticians (seven UCSF faculty, two are UCSF staff) who provide the extensive breadth of expertise required for Cancer Center projects. CCSG support pays for consulting and grant development services provided to Cancer Center researchers, protocol review services in PRMS and DSMC. CCSG support provides from 25 - 30% salary support for the faculty statisticians. Each statistician has the remainder of their support provided through scientific collaborations with other Cancer Center investigators, from grants for their own research, and from direct support from the Departments in which they work.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388381
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$533,749
Indirect Cost
$192,877
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications